Greentech company AFYREN (Euronext Paris:ALAFY) said on Thursday that it its 100% bio-based, COSMOS-certified propionic acid has enabled the global launch of Esse Barrier Rescue, developed with South Africa-based microbiome skincare company Esse Skincare.
The product is described as the world's first skincare product formulated with natural propionic acid and combines the ingredient with ceramides to target extremely dry and reactive skin while supporting the skin's natural ecosystem.
Propionic acid is a naturally occurring short-chain fatty acid associated with maintaining skin microbiome balance, with emerging research indicating potential roles in inflammation modulation, barrier resilience and microbial balance.
AFYREN produces its propionic acid through natural fermentation at its AFYREN NEOXY industrial biorefinery, using a circular, low-carbon process.
The partnership provides Esse with a bio-based alternative to propionic acid traditionally produced at industrial scale from petrochemical sources.
AFYREN said the collaboration demonstrates the potential of its ingredients to support new cosmetic applications and expand the use of bio-based materials in skincare.
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
AFYREN ingredient enables global launch of natural propionic acid skincare product
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
XtalPi submits US FDA IND application for KQTD-126 in chronic intestinal pain
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Teva reports positive Phase 2a data for TEV '408 in celiac disease
AbbVie seeks EMA approval for subcutaneous induction of risankizumab in Crohn's disease